Gonadorelin, also known as gonadotropin-releasing hormone (GnRH) or luteinizing hormone–releasing hormone (LHRH), is a synthetic decapeptide widely utilized as a laboratory reagent for investigating GnRH receptor (GnRHR) signaling and hypothalamic–pituitary–gonadal (HPG) axis regulation in experimental systems. In preclinical and in vitro models, GnRHR activation on pituitary gonadotrophs initiates tightly regulated intracellular signaling cascades that control gonadotropin synthesis and secretion. Due to its well-defined receptor specificity and signaling profile, gonadorelin is commonly employed in receptor pharmacology, endocrine pathway mapping, and systems-level studies of hormone-regulated biological networks.

Source: PubChem

Sequence: Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly
Molecular Formula: C₅₅H₇₅N₁₇O₁₃
Molecular Weight: 1182.311 g/mol
PubChem CID: 638793
CAS Number: 9034-40-6
Synonyms: Gonadotropin-Releasing Hormone, GnRH, LHRH

Gonadorelin functions as an agonist at the GnRH receptor, a class A G protein–coupled receptor predominantly expressed on pituitary gonadotrophs in commonly used laboratory species. In cellular and ex vivo preparations, receptor activation is typically coupled to G_q/11-mediated phospholipase C activation, resulting in inositol trisphosphate and diacylglycerol production, intracellular calcium mobilization, and protein kinase C signaling. These proximal events engage downstream kinase cascades, including MAPK/ERK pathways, which regulate transcriptional control of gonadotropin subunit genes and secretory machinery.

In whole-animal experimental models, controlled modulation of GnRHR signaling is frequently used to perturb endocrine feedback loops within the HPG axis. Quantitative analysis of gonadotropin output, steroidogenic enzyme expression, and steroid receptor–mediated transcriptional responses enables mechanistic interrogation of endocrine network architecture and signal integration across tissues.

GnRH signaling effects on gonadotropin regulation
Source: PubMed

Gonadorelin is employed exclusively as a research reagent in laboratory settings to support mechanistic and exploratory investigations of endocrine signaling. Common experimental applications include GnRHR pharmacology (agonist potency, efficacy, signaling bias, and receptor desensitization), second-messenger and kinase pathway analysis, endocrine feedback modeling in animal systems, and integrated omics approaches linking controlled GnRH pathway activation to transcriptional, proteomic, and metabolomic outputs in target tissues and cultured cells.

The referenced scientific literature consists solely of preclinical and mechanistic studies conducted in cellular systems and animal models. These investigations utilize GnRH pathway modulation as an experimental variable to examine endocrine signaling dynamics, steroidogenic pathway regulation, hormone-responsive transcriptional programs, and neuroendocrine signal integration. All reported findings are context-dependent and limited to the specific experimental systems, species, and analytical methodologies described in the cited publications.

This product is supplied as a lyophilized peptide intended for laboratory research workflows. Standard characterization may include chromatographic analysis (HPLC or UPLC) and mass spectrometry for identity confirmation and purity assessment. Proper handling and storage should follow established laboratory protocols for peptide stability, including controlled temperature storage, minimization of freeze–thaw cycles, and maintenance of lot traceability.

The above literature was researched, edited and organized by Dr. Logan, M.D. Dr. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Dr. Giorgio Secreto currently studies at the IRCCS National Cancer Institute in Italy. His accolades include, a 1963 High School degree, Maturità Classica 1969 Degree in Medicine and Surgery, University of Milan, Italy 1974 Degree Specialist in Endocrinology, University of Turin, Italy. Doctor Secreto has been working at the National Cancer Institute of Milan since 1970 up to now, after his retirement in December 2010. The role of androgens in breast cancer is his main field of study. He has been teacher at the Italian School of Senology (1989-1996), Associate Professor in Oncology, L.U.de.S. University, Lugano, Switzerland (1999-2008), and Associate Professor in Endocrinology, Nurses’ School, University of Milan (2003-2008). He is active member of the New York Academy of Sciences and the American Association for the Advancement of Sciences. He published about 100 papers, including a few that pertain to GnRH’s effects on the reduction of breast cancer via minimizing excessive androgens.

Dr. Giorgio Secreto is being referenced as one of the leading scientists involved in the research and development of Gonadorelin. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Doctor Secreto is listed in [1] and [3] under the referenced citations.

1. G. Secreto et al., “A novel approach to breast cancer prevention: reducing excessive ovarian androgen production in elderly women,” Breast Cancer Res. Treat., vol. 158, no. 3, pp. 553–561, 2016.
2. D. V. Spicer and M. C. Pike, “Sex steroids and breast cancer prevention,” J. Natl. Cancer Inst. Monogr., no. 16, pp. 139–147, 1994.
3. G. Secreto, P. Muti, M. Sant, E. Meneghini, and V. Krogh, “Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy,” Endocr. Relat. Cancer, vol. 24, no. 11, pp. C21–C29, 2017.
4. E. S. Vollaard, A. P. van Beek, F. A. J. Verburg, A. Roos, and J. A. Land, “Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin,” J. Clin. Endocrinol. Metab., vol. 96, no. 5, pp. 1197–1201, May 2011.
5. F. Labrie, “Hormonal therapy of prostate cancer,” Prog. Brain Res., vol. 182, pp. 321–341, 2010.
6. F. Labrie, “GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer,” Endocr. Relat. Cancer, vol. 21, no. 4, pp. R301-317, Aug. 2014.
7. F. Labrie, “Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology,” J. Steroid Biochem. Mol. Biol., vol. 145, pp. 144–156, Jan. 2015.
8. F. Labrie, “[Keyrole of endocrinology in the victory against prostate cancer],” Bull. Cancer (Paris), vol. 93, no. 9, pp. 949–958, Sep. 2006.
9. V. Burnham, C. Sundby, A. Laman-Maharg, and J. Thornton, “Luteinizing hormone acts at the hippocampus to dampen spatial memory,” Horm. Behav., vol. 89, pp. 55–63, 2017.
10. C. V. Rao, “Involvement of Luteinizing Hormone in Alzheimer Disease Development in Elderly Women,” Reprod. Sci. Thousand Oaks Calif, vol. 24, no. 3, pp. 355–368, 2017.
11. J. Lin et al., “Genetic ablation of luteinizing hormone receptor improves the amyloid pathology in a mouse model of Alzheimer disease,” J. Neuropathol. Exp. Neurol., vol. 69, no. 3, pp. 253–261, Mar. 2010.
12. R. L. Bowen, T. Butler, and C. S. Atwood, “Not All Androgen Deprivation Therapies Are Created Equal: Leuprolide and the Decreased Risk of Developing Alzheimer’s Disease,” J. Clin. Oncol., vol. 34, no. 23, p. 2800, Aug. 2016.
13. M. A. Smith, R. L. Bowen, R. Q. Nguyen, G. Perry, C. S. Atwood, and A. A. Rimm, “Putative Gonadotropin-Releasing Hormone Agonist Therapy and Dementia: An Application of Medicare Hospitalization Claims Data,” J. Alzheimers Dis. JAD, vol. 63, no. 4, pp. 1269–1277, 2018.
14. A. Cáceres, J. E. Vargas, and J. R. González, “APOE and MS4A6A interact with GnRH signaling in Alzheimer’s disease: Enrichment of epistatic effects,” Alzheimers Dement. J. Alzheimers Assoc., vol. 13, no. 4, pp. 493–497, Apr. 2017.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.